NDAORALTABLET
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ATTRUBY (acoramidis hydrochloride) is a newly approved oral small-molecule tablet indicated for a rare or orphan disease, approved by FDA on November 22, 2024. The mechanism of action and specific indication are not yet publicly detailed, but the drug represents BridgeBio Pharma's entry into a niche therapeutic area. As a growth-stage product with 13+ years of patent protection, ATTRUBY is positioned for early commercial expansion.
Growth13.0 years to LOE
As a newly launched, patent-protected product with zero competitive pressure, ATTRUBY offers growth-stage opportunity for commercial teams to establish market position and build reimbursement infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
BridgeBio Pharma is hiring 1 role related to this product
Worked on ATTRUBY at BridgeBio Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.